IgM myeloma: A multicenter retrospective study of 134 patients

Jorge J. Castillo, Artur Jurczyszyn, Lucie Brozova, Edvan Crusoe, Jacek Czepiel, Julio Davila, Angela Dispenzieri, Marion Eveillard, Mark A. Fiala, Irene M. Ghobrial, Alessandro Gozzetti, Joshua N. Gustine, Roman Hajek, Vania Hungria, Jiri Jarkovsky, David Jayabalan, Jacob P. Laubach, Barbara Lewicka, Vladimir Maisnar, Elisabet E. ManasanchPhilippe Moreau, Elizabeth A. Morgan, Hareth Nahi, Ruben Niesvizky, Claudia Paba-Prada, Tomas Pika, Ludek Pour, John L. Reagan, Paul G. Richardson, Jatin Shah, Ivan Spicka, Ravi Vij, Anna Waszczuk-Gajda, Morie Gertz

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL−1 with 19% of patients presenting with levels >6,000 mg dL−1. International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

Original languageEnglish (US)
Pages (from-to)746-751
Number of pages6
JournalAmerican Journal of Hematology
Volume92
Issue number8
DOIs
StatePublished - Aug 1 2017

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'IgM myeloma: A multicenter retrospective study of 134 patients'. Together they form a unique fingerprint.

  • Cite this

    Castillo, J. J., Jurczyszyn, A., Brozova, L., Crusoe, E., Czepiel, J., Davila, J., Dispenzieri, A., Eveillard, M., Fiala, M. A., Ghobrial, I. M., Gozzetti, A., Gustine, J. N., Hajek, R., Hungria, V., Jarkovsky, J., Jayabalan, D., Laubach, J. P., Lewicka, B., Maisnar, V., ... Gertz, M. (2017). IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 92(8), 746-751. https://doi.org/10.1002/ajh.24753